Solid Biosciences (NASDAQ: SLDB) sets $200M stock sale capacity
Rhea-AI Filing Summary
Solid Biosciences Inc. filed a prospectus supplement on August 6, 2026 under its universal shelf registration statement on Form S-3 (File No. 333-287325), covering the offer and sale of up to $200.0 million of common stock pursuant to an Amended and Restated Sales Agreement with Jefferies LLC.
This new supplement follows a prior prospectus supplement under a different Form S-3 that permitted up to $85.0 million of common stock sales; as of the new filing, the company has issued and sold shares for aggregate gross proceeds of approximately $85.0 million under that earlier capacity and will no longer use it for additional sales. A legal opinion from Wilmer Cutler Pickering Hale and Dorr LLP regarding the shares is filed as Exhibit 5.1, and offerings will be made only by means of the new prospectus supplement and base prospectus.
Positive
- None.
Negative
- None.
Filing Explained
The August 6 8-K reports a prospectus supplement establishing up to
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
New common stock capacity: $200.0 million
Prior supplement capacity: $85.0 million
Gross proceeds realized: $85.0 million
+2 more
5 metrics
New common stock capacity
$200.0 million
Total common stock that may be offered under the August 6, 2026 prospectus supplement
Prior supplement capacity
$85.0 million
Aggregate offering price of common stock covered by the prior prospectus supplement
Gross proceeds realized
$85.0 million
Aggregate gross sale proceeds from shares sold under the Sales Agreement and Prior Prospectus Supplement
S-3 effectiveness date
May 27, 2025
Date the Form S-3 (File No. 333-287325) was declared effective by the SEC
Sales Agreement date
March 13, 2024
Date of the Amended and Restated Sales Agreement with Jefferies LLC
Key Terms
universal shelf registration statement, prospectus supplement, Form S-3, base prospectus, +2 more
6 terms
universal shelf registration statement regulatory
"under the Company’s universal shelf registration statement on Form S-3"
A universal shelf registration statement is a standing registration filed with regulators that lets a company and authorized sellers offer and sell many kinds of securities (stock, bonds, warrants, etc.) over time without filing a new registration each time. For investors it matters because it gives the issuer the flexibility to raise cash or let insiders sell shares quickly, which can change the supply of securities, affect share price and dilution, and influence liquidity—like a store having a pre-approved plan to add new items to its shelves as needed.
prospectus supplement regulatory
"filed a prospectus supplement under the Company’s universal shelf registration"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
Form S-3 regulatory
"universal shelf registration statement on Form S-3 (File No. 333-287325)"
Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.
base prospectus regulatory
"The Shares are registered pursuant to the Registration Statement and the base prospectus"
A base prospectus is a detailed document that provides essential information about a financial offering, such as a bond or share issue. It acts like a comprehensive guide for investors, explaining what the investment involves, the risks involved, and how the process works. This helps investors make informed decisions before committing their money.
Registration Statement regulatory
"The Shares are registered pursuant to the Registration Statement and the base prospectus"
A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.
emerging growth company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Solid Biosciences (SLDB) report on August 6, 2026?
Solid Biosciences filed a prospectus supplement under its Form S-3 shelf to cover the offer and sale of up to $200.0 million of common stock pursuant to an Amended and Restated Sales Agreement with Jefferies LLC.
How large is Solid Biosciences’ new common stock capacity under the latest supplement?
The new prospectus supplement covers up to $200.0 million of Solid Biosciences common stock. These shares are registered under the company’s Form S-3 universal shelf registration statement and may be sold pursuant to a Sales Agreement with Jefferies LLC.
What happened to Solid Biosciences’ prior $85.0 million prospectus supplement?
A prior prospectus supplement allowed sales of up to $85.0 million of common stock. Solid Biosciences has already issued and sold shares for aggregate gross proceeds of about $85.0 million under it and will not make further offers or sales using that prior supplement.
Which registration statement now covers the new Solid Biosciences (SLDB) offering?
The new offering is covered by Solid Biosciences’ universal shelf registration statement on Form S-3 (File No. 333-287325), filed May 15, 2025 and declared effective by the SEC on May 27, 2025.
Who is Solid Biosciences’ sales agent under the common stock Sales Agreement?
Solid Biosciences sells common stock pursuant to an Amended and Restated Sales Agreement with Jefferies LLC, dated March 13, 2024. The new prospectus supplement allows continued use of this agreement for future common stock offerings.